PureTech Health plc (PRTC)

NASDAQ

$17.25

+$0.34 (2.01%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$16.88$17.25

Open $16.88

52 Week Range

$13.30$23.35

Previous Close $16.91

Market Cap416.90M

Volume7

Avg Volume3.64K

P/E (TTM)7.99

EPS (TTM)$2.16

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for PureTech Health plc

DEC82025

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

Source: Business Wire•8 days ago

BOSTON--(BUSINESS WIRE)--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis....

DEC52025

PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Source: Business Wire•10 days ago

BOSTON--(BUSINESS WIRE)--PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data for LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia....

OCT222025

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

Source: Business Wire•55 days ago

BOSTON--(BUSINESS WIRE)--PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with IPF....

SEP292025

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

Source: Business Wire•78 days ago

BOSTON--(BUSINESS WIRE)--PureTech Presents New Data from Deupirfenidone Phase 2b Open-Label Extension, Further Supporting Potential to Serve as New Standard of Care in IPF....